This is a preview of subscription content, log in via an institution to check access.
Notes
The study was affiliated with Agios Pharmaceuticals.
Reference
Su W, et al. The Lifetime Economic Burden of Pyruvate Kinase Deficiency in the United States. 26th Congress of the European Haematology Association : abstr. EP1194, 9 Jun 2021. Available from: URL: https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324915/erin.zagadailov.the.lifetime.economic.burden.of.pyruvate.kinase.deficiency.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2035%2Aot_id%3D25575%2Amarker%3D1286%2Afeatured%3D17286
Rights and permissions
About this article
Cite this article
Economic burden of pyruvate kinase deficiency high for healthcare payers in the USA. PharmacoEcon Outcomes News 884, 14 (2021). https://doi.org/10.1007/s40274-021-7921-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7921-7